Trial Profile

Open Label Multicenter Randomized Trial Comparing Standard Immunosuppression With Tacrolimus and Mycophenolate Mofetil With a Low Exposure Tacrolimus Regimen in Combination With Everolimus in de Novo Renal Transplantation in Elderly Patient

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Tacrolimus (Primary) ; Basiliximab; Ciclosporin; Mycophenolate mofetil; Mycophenolic acid; Prednisolone
Indications Renal transplant rejection
Focus Therapeutic Use
Acronyms OPTIMIZE

09 May 2023 Status changed from recruiting to active, no longer recruiting.
11 May 2022 Results of substudy assessing humoral response after 2 and 3 COVID-19 mRNA vaccinations and the cellular response after vaccinations published in the Transplantation
07 Jan 2020 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com